Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.0977
Abstract: This study estimates the total costs associated with administering chimeric antigen receptor T-cell treatment. read more here.
Keywords: total costs; antigen receptor; chimeric antigen; receptor cell ... See more keywords
Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26506
Abstract: CD19‐targeted chimeric antigen receptor T (CAR‐T) cells using murine single‐chain variable fragment (scFv) has shown substantial clinical efficacy in treating relapsed/refractory acute lymphoblastic leukemia (R/R ALL). However, potential immunogenicity of the murine scFv domain may… read more here.
Keywords: antigen receptor; refractory acute; relapsed refractory; chimeric antigen ... See more keywords
A novel adoptive synthetic TCR and antigen receptor (STAR) T‐Cell therapy for B‐Cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26586
Abstract: We developed a T‐cell‐receptor (TCR) complex‐based chimeric antigen receptor (CAR) named Synthetic TCR and Antigen Receptor (STAR). Here, we report pre‐clinical and phase I clinical trial data (NCT03953599) of this T‐cell therapy for refractory and… read more here.
Keywords: cell; tcr; star; antigen receptor ... See more keywords
Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United States
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4797
Abstract: It is not clear if all Americans have benefitted equally from the availability of chimeric antigen receptor T‐cell (CART) therapy. We aimed to evaluate if demographic differences existed among adult patients who received CART therapy… read more here.
Keywords: demographic differences; antigen receptor; receptor cell; chimeric antigen ... See more keywords
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5551
Abstract: Over the last decade, the emergence of several novel therapeutic approaches has changed the therapeutic perspective of human malignancies. Adoptive immunotherapy through chimeric antigen receptor T cell (CAR‐T), which includes the engineering of T cells… read more here.
Keywords: cell; antigen receptor; chimeric antigen; cell therapy ... See more keywords
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34532
Abstract: Autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR… read more here.
Keywords: cell; antigen receptor; chimeric antigen; cd19 chimeric ... See more keywords
Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T‐cell therapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34557
Abstract: Chimeric antigen receptor (CAR) T‐cell is potentially curative therapy for patients with hematologic malignancies but can cause life‐threatening toxicities. Data on perceptions of prognosis and psychological distress are lacking. read more here.
Keywords: cell; therapy; chimeric antigen; antigen receptor ... See more keywords
Microraft arrays for serial‐killer CD19 chimeric antigen receptor T cells and single cell isolation
Sign Up to like & getrecommendations! Published in 2022 at "Cytometry Part A"
DOI: 10.1002/cyto.a.24678
Abstract: Chimeric antigen receptor T (CAR‐T) cell immunotherapies have seen success in treating hematological malignancies in recent years; however, the results can be highly variable. Single cell heterogeneity plays a key role in the variable efficacy… read more here.
Keywords: cell; antigen receptor; microraft; chimeric antigen ... See more keywords
Antigen receptor‐engineered Tregs inhibit CNS autoimmunity in cell therapy using nonredundant immune mechanisms in mice
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Immunology"
DOI: 10.1002/eji.202249845
Abstract: CD4+FOXP3+ Tregs are currently explored to develop cell therapies against immune‐mediated disorders, with an increasing focus on antigen receptor‐engineered Tregs. Deciphering their mode of action is necessary to identify the strengths and limits of this… read more here.
Keywords: cell therapy; receptor engineered; engineered tregs; antigen receptor ... See more keywords
Chimeric antigen receptor–based therapies beyond cancer
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Immunology"
DOI: 10.1002/eji.202250184
Abstract: Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein… read more here.
Keywords: antigen receptor; chimeric antigen; car; receptor based ... See more keywords
Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2672
Abstract: Ninety percent of relapse/refractory B‐cell acute lymphatic leukemia (R/R B‐ALL) patients can achieve complete remission (CR) after CD19‐targeting chimeric antigen receptor T (CAR‐T) cell therapy. However, around 50% of them relapse in 1 year. Persistent… read more here.
Keywords: antigen receptor; cd19; phase study; leukemia ... See more keywords